Cushing's Syndrome and Other Causes of Insulin Resistance in Dogs.
Fleeman L, Barrett R.
Vet Clin North Am Small Anim Pract. 2023 May;53(3):711-730. doi: 10.1016/j.cvsm.2023.01.009. Epub 2023 Mar 8.
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A Review.
DeFronzo RA, Auchus RJ.
Diabetes. 2025 Dec 1;74(12):2168-2178. doi: 10.2337/db25-0120.
Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?
Krarup T, Krarup T, Hagen C.
Diabetes Metab Res Rev. 2012 Mar;28(3):219-27. doi: 10.1002/dmrr.2262.
Management of diabetes mellitus in Cushing's syndrome.
Munir A, Newell-Price J.
Neuroendocrinology. 2010;92 Suppl 1:82-5. doi: 10.1159/000314316. Epub 2010 Sep 10.
Pathophysiology of diabetes mellitus in Cushing's syndrome.
Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, Lombardi G, Colao A.
Neuroendocrinology. 2010;92 Suppl 1:77-81. doi: 10.1159/000314319. Epub 2010 Sep 10.
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.
Buse JB, Kahn SE, Aroda VR, Auchus RJ, Bailey T, Bancos I, Busch RS, Christofides EA, DeFronzo RA, Eilerman B, Findling JW, Fonseca V, Hamidi O, Handelsman Y, Miller HJ, Ownby JG, Parker JC, Philis-Tsimikas A, Pratley R, Rosenstock J, Shanik MH, Sloan LL, Umpierrez G, Tudor IC, Schlafly TK, Einhorn D; CATALYST Investigators*.
Diabetes Care. 2025 Dec 1;48(12):2012-2020. doi: 10.2337/dc24-2841.
Cushing's syndrome is associated with altered adipokine profile.
Dadej D, Szczepanek-Parulska E, Wrotkowska E, Ruchała M.
Front Endocrinol (Lausanne). 2022 Dec 6;13:1032329. doi: 10.3389/fendo.2022.1032329. eCollection 2022.
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study.
Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG.
Front Endocrinol (Lausanne). 2021 Jul 14;12:662865. doi: 10.3389/fendo.2021.662865. eCollection 2021.
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.
Guarnotta V, Emanuele F, Salzillo R, Bonsangue M, Amato C, Mineo MI, Giordano C.
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
Approach to the Patient with Subclinical Cushing's Syndrome.
Ivović M, Marina LV, Šojat AS, Tančić-Gajić M, Arizanović Z, Kendereški A, Vujović S.
Curr Pharm Des. 2020;26(43):5584-5590. doi: 10.2174/1381612826666200813134328.
